drugset / Trial / NCT06189170
Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients
RandomizedSequentialDouble-blindTreatment
Summary
This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2025-12-31
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KP405 | Unknown | — | — |
Indications
No indication recorded.